Abstract

Jerry Wolinsky, Emeritus Professor of Neurology at the University of Texas Health Science Center (Houston, TX, USA), sent me a picture of himself holding a walleye (Sander vitreus), caught at the Lake of the Woods in Ontario, Canada. Behind him is a hint of the landscape for which the area is renowned. I first thought it unsuitable for a Profile shot, but after our conversation I understood it in a new light, one that reflects Jerry's perception of his career: you can sometimes stand out against a landscape, but if the viewer draws back, you always become part of a bigger picture. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialCompared with patients switching from placebo, earlier and continuous ocrelizumab treatment provided sustained benefits on measures of disease progression over the 6·5 study years of follow-up. Although this study shows the benefit of earlier intervention with ocrelizumab in primary progressive disease, progression remains an important unmet need in multiple sclerosis. Further research should focus on how the potential benefits described in this study might be improved upon, particularly over longer time periods. Full-Text PDF

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.